Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer

KIZ OpenIR > 科研部门 > 肿瘤生物学（陈策实）

	Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer
	Guo, YX; Li, YZ; Zhou, ZM; Hou, L; Liu, WJ; Ren, WL; Mi, DZ; Sun, J; Dai, XQ; Wu, YY; Cheng, Z; Wu, TY; Luo, QM; Tian, C; Li, FB; Yu, ZG; Chen, YH; Chen, CS
	2024
发表期刊	J EXP CLIN CANC RES
卷号	43 期号:1
摘要	BackgroundTriple-negative breast cancer (TNBC) is currently the most aggressive subtype of breast cancer, characterized by high heterogeneity and strong invasiveness, and currently lacks effective therapies. PRMT5, a type II protein arginine methyltransferase, is upregulated in numerous cancers, including TNBC, and plays a critical role, marked it as an attractive therapeutic target. PROTAC (Proteolysis Targeting Chimeras) is an innovative drug development technology that utilizes the ubiquitin-proteasome system (UPS) to degrade target proteins, which is characterized by higher activity, enhanced safety, lower resistance, and reduced toxicity, offering significant value for clinical translation.MethodsThis study utilizes the PROTAC technology to develop potential degraders targeting PRMT5 in vitro and in vivo.ResultsThrough the design, synthesis and screening of a series of targeted compounds, we identified YZ-836P as an effective compound that exerted cytotoxic effects and reduced the protein levels of PRMT5 and its key downstream target protein KLF5 in TNBC after 48 h. Its efficacy was significantly superior to the PRMT5 PROTAC degraders that had been reported. YZ-836P induced G1 phase cell cycle arrest and significantly induced apoptosis in TNBC cells. Additionally, we demonstrated that YZ-836P promoted the ubiquitination and degradation of PRMT5 in a cereblon (CRBN)-dependent manner. Notably, YZ-836P exhibited pronounced efficacy in inhibiting the growth of TNBC patient-derived organoids and xenografts in nude mice.ConclusionsThese findings position YZ-836P as a promising candidate for advancing treatment modalities for TNBC.Trial registrationEthics Committee of Yunnan Cancer Hospital, KYCS2023-078. Registered 7 June 2023.
收录类别	SCI
语种	英语
文献类型	期刊论文
条目标识符	http://ir.kiz.ac.cn/handle/152453/14620
专题	科研部门_肿瘤生物学（陈策实）
推荐引用方式 GB/T 7714	Guo, YX,Li, YZ,Zhou, ZM,et al. Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer[J]. J EXP CLIN CANC RES,2024,43(1).
APA	Guo, YX.,Li, YZ.,Zhou, ZM.,Hou, L.,Liu, WJ.,...&Chen, CS.(2024).Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer.J EXP CLIN CANC RES,43(1).
MLA	Guo, YX,et al."Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer".J EXP CLIN CANC RES 43.1(2024).

条目包含的文件
文件名称/大小	文献类型	版本类型	开放类型	使用许可
CCS2025042103.pdf（2712KB）	期刊论文	出版稿	开放获取	CC BY-NC-SA	请求全文